Clinical trials: Stage 1 Hypertension
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Renal Artery Stenosis, Ischemic Nephropathy
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC.
- Conditions
- Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
- Trial name
- NCT02266394
- Testing
- Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Elevated Blood Pressure, Hypertension
Study to Investigate the Potential Health Benefits of Grapes Seeds Extract Supplementation in the Management of Elevated Blood Pressure or Stage 1 Hypertension
This study is a pragmatic, randomized, double-blind, placebo-controlled trial aimed at evaluating the potential health benefits of Enovita® (standardized grape seed extract) supplementation in adults with elevated blood pressure…
- Trial name
- NCT06982365
- Testing
- Enovita® (Grape Seed Extract)
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Essential Hypertension
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
- Trial name
- NCT07282145
- Testing
- BCD101 Low Dose Liquid Formulation, BCD101 High Dose Liquid Formulation, BCD101 Low + High Dose Liquid Formulation
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bichedam Co., Ltd.
Essential Hypertension
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32…
- Trial name
- NCT01873885
- Testing
- Experimental: Single IV Infusion Vasomera (PB1046)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Prehypertension
Diet and Exercise on Ambulatory Blood Pressure
This is a multicenter, randomized, single-blinded clinical trial investigating the effect of dietary management and active aerobic exercise training on reduction of 24-hour ambulatory blood pressure in subjects with…
- Trial name
- NCT05274971
- Testing
- Active dietary management and aerobic exercise training.
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Overweight , Obesity, Class I Obesity
Dietary Guidelines for Americans-Ultra Processed Study
The purpose of this research is to test how processing food can affect how one's body responds to it.
- Trial name
- DGA-UP (NCT07252037)
- Testing
- Low-processed DGA Diet, Ultra-processed DGA Diet
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Postmenopausal Syndrome, Hypertension
Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women
The purpose of this study is to demonstrate better effectiveness of modified relaxation (MR) technique over no MR for treating hypertension in Thai postmenopausal women.
- Trial name
- NCT01429662
- Testing
- Modified Relaxation (MR), Lifestyle Education (LE)
- Where
- Thailand
- Volunteers
- 429 people
- Sponsor
- Chiang Mai University
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Uncontrolled Hypertension
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
- Trial name
- NCT07051603
- Testing
- SAL0140
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Resistant Hypertension
JX09 SAD/MAD in Healthy Participants
This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09…
- Trial name
- NCT06183671
- Testing
- JX09
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Ji Xing Pharmaceuticals Australia Pty Ltd
Hypertension, COVID-19
ARB, ACEi, DRi Effects on COVID-19 Course Disease
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2.
- Trial name
- BIRCOV (NCT04364984)
- Testing
- Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, Direct renin inhibitor
- Where
- Ukraine
- Volunteers
- 112 people
- Sponsor
- Medical Practice Prof D. Ivanov
Hypertension
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
The goal of this Phase 1, open-label, single-dose, parallel-group study is to evaluate the pharmacokinetics (PK) of a single 10-mg oral dose of baxdrostat in subjects with varying degrees of hepatic function.
- Trial name
- NCT05961397
- Testing
- baxdrostat
- Where
- 5 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Hypertension
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg/hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1…
- Trial name
- NCT00240448
- Testing
- telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg
- Where
- 100 sites in United States
- Volunteers
- 1,109 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health…
- Trial name
- LIBERTY (NCT02664558)
- Testing
- ubenimex
- Where
- 31 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Eiger BioPharmaceuticals
Hypertension
L-arginine Treatment in Mild Hypertension
Essential Hypertension is characterized by endothelial dysfunction due to reduced nitric oxide (NO) bioavailability. Impairment in nitric oxide-mediated vasodilatation in human brachial, coronary, and renal arteries has been…
- Trial name
- LAHN (NCT02894723)
- Testing
- L-arginine, syrup
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Meir Medical Center
Hypertension, Cardiovascular Diseases
Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.
The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the…
- Trial name
- NCT05798481
- Testing
- Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies